Changes in Beneficial Ownership · 4
Q32 Bio Inc.
QTTBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-06
- Issuer
- Q32 Bio Inc.
- Issuer CIK
- 0001661998
- Trading symbol
- QTTB
Reporting owner 1
- Name
- Kalowski Lee
- Reporting owner CIK
- 0001618273
- Relationship
- Officer
- Officer title
- CFO and President
- Address
- Q32 BIO INC., 830 WINTER STREET, WALTHAM, MA, 02451
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-06 | S · Form 4[F1] | 1,301 | D | 8.3198[F2] | 137,170 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.↩ 1
Signature 1
- Signed
- /s/ Eric Bell, Attorney-in-Fact
- Date
- 2026-10-14
Company context
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.